These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 28059068)

  • 21. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma.
    Ku BM; Yi SY; Koh J; Bae YH; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Oncotarget; 2016 Mar; 7(12):14803-13. PubMed ID: 26909611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
    Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
    PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.
    Martin CA; Cullinane C; Kirby L; Abuhammad S; Lelliott EJ; Waldeck K; Young RJ; Brajanovski N; Cameron DP; Walker R; Sanij E; Poortinga G; Hannan RD; Pearson RB; Hicks RJ; McArthur GA; Sheppard KE
    Int J Cancer; 2018 May; 142(10):2139-2152. PubMed ID: 29243224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.
    Tricker EM; Xu C; Uddin S; Capelletti M; Ercan D; Ogino A; Pratilas CA; Rosen N; Gray NS; Wong KK; Jänne PA
    Cancer Discov; 2015 Sep; 5(9):960-971. PubMed ID: 26036643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma.
    Gao W; Liu S; Wu Y; Wei W; Yang Q; Li W; Chen H; Luo A; Wang Y; Liu Z
    EBioMedicine; 2024 Jul; 105():105177. PubMed ID: 38924839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.
    Rose M; Maurer A; Wirtz J; Bleilevens A; Waldmann T; Wenz M; Eyll M; Geelvink M; Gereitzig M; Rüchel N; Denecke B; Eltze E; Herrmann E; Toma M; Horst D; Grimm T; Denzinger S; Ecke T; Vögeli TA; Knuechel R; Maurer J; Gaisa NT
    Oncogene; 2020 Oct; 39(44):6856-6870. PubMed ID: 32978523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
    Sobhakumari A; Orcutt KP; Love-Homan L; Kowalski CE; Parsons AD; Knudson CM; Simons AL
    Oncol Res; 2016; 24(1):55-64. PubMed ID: 27178822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.
    Chaudhary S; Pothuraju R; Rachagani S; Siddiqui JA; Atri P; Mallya K; Nasser MW; Sayed Z; Lyden ER; Smith L; Gupta SD; Ralhan R; Lakshmanan I; Jones DT; Ganti AK; Macha MA; Batra SK
    Cancer Lett; 2021 Jul; 510():79-92. PubMed ID: 33878394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines.
    Boeckx C; Van den Bossche J; De Pauw I; Peeters M; Lardon F; Baay M; Wouters A
    BMC Res Notes; 2015 Jun; 8():203. PubMed ID: 26032726
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition.
    Luo QY; Zhou SN; Pan WT; Sun J; Yang LQ; Zhang L; Qiu MZ; Yang DJ
    Biochem Pharmacol; 2021 Jan; 183():114318. PubMed ID: 33159967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
    Van Allen EM; Lui VW; Egloff AM; Goetz EM; Li H; Johnson JT; Duvvuri U; Bauman JE; Stransky N; Zeng Y; Gilbert BR; Pendleton KP; Wang L; Chiosea S; Sougnez C; Wagle N; Zhang F; Du Y; Close D; Johnston PA; McKenna A; Carter SL; Golub TR; Getz G; Mills GB; Garraway LA; Grandis JR
    JAMA Oncol; 2015 May; 1(2):238-44. PubMed ID: 26181029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer.
    Sutter AP; Höpfner M; Huether A; Maaser K; Scherübl H
    Int J Cancer; 2006 Apr; 118(7):1814-22. PubMed ID: 16217753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
    Jimeno A; Kulesza P; Wheelhouse J; Chan A; Zhang X; Kincaid E; Chen R; Clark DP; Forastiere A; Hidalgo M
    Br J Cancer; 2007 Mar; 96(6):952-9. PubMed ID: 17342092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway.
    Ma P; Fu Y; Chen M; Jing Y; Wu J; Li K; Shen Y; Gao JX; Wang M; Zhao X; Zhuang G
    Theranostics; 2016; 6(8):1232-43. PubMed ID: 27279914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.
    Cui G; Cui M; Li Y; Liang Y; Li W; Guo H; Zhao S
    Med Oncol; 2015 Apr; 32(4):124. PubMed ID: 25788032
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.